|
Cell line
|
Patient age (years)
|
Patient Survival (Days)
|
RB pathway LOF
|
Cell line doubling time (hours)
|
XG median survival (days)
|
|---|
|
BAH1
|
75
|
94
|
Yes
|
79.5 ± 3.3
|
210 ± 8
|
|
FPW1
|
68
|
242
|
Yes
|
48.1 ± 4.7
|
196 ± 4
|
|
HW1
|
54
|
89
|
Yes
|
55.8 ± 2.7
|
174 ± 14
|
|
JK2
|
75
|
178
|
Yes
|
94.2 ± 4.5
|
147 ± 9
|
|
MMK1
|
80
|
334
|
Yes
|
52.4 ± 3.3
|
157 ± 15
|
|
MN1
|
84
|
36
|
Yes
|
44.9 ± 1.0
|
258 ± 20
|
|
PB1
|
57
|
39
|
Yes
|
79.4 ± 6.3
|
71 ± 1
|
|
RKI1
|
57
|
Alive (7 years)
|
No
|
72.9 ± 5.3
|
248 ± 6
|
|
RN1
|
56
|
243
|
Yes
|
37.5 ± 1.9
|
81 ± 2
|
|
SB2b
|
48
|
420
|
Yes
|
108.7 ± 6.9
|
120 ± 3.3
|
|
SJH1
|
72
|
45
|
Yes
|
67.3 ± 4.7
|
148 ± 4
|
|
WK1
|
77
|
121
|
Yes
|
46.2 ± 1.0
|
150 ± 2
|
- Metadata for patient age and survival post-diagnosis along with retinoblastoma status, doubling time for the derived cell lines and median survival of mice carrying orthotopic tumours. RB pathway LOF Loss of function in one or more steps in the retinoblastoma tumour suppressor pathway. XG median survival Median survival for mice with orthotopic xenografts
